STOCK TITAN

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Delcath Systems (Nasdaq: DCTH), an interventional oncology company specializing in liver cancer treatments, has announced equity inducement grants to six new employees who joined in January and February 2025. The grants include options to purchase 264,000 shares of common stock under the company's 2023 Inducement Plan.

The stock options were granted on February 28, 2025, with an exercise price of $14.17 per share, matching the closing price of Delcath's common stock on that date. The vesting schedule includes one-third of options vesting after the first year, with the remaining two-thirds vesting in equal monthly installments over 24 months. The options have a ten-year term and require continued employment for vesting.

Delcath Systems (Nasdaq: DCTH), un'azienda di oncologia interventistica specializzata nei trattamenti per il cancro al fegato, ha annunciato concessioni di incentivi azionari a sei nuovi dipendenti che si sono uniti a gennaio e febbraio 2025. Le concessioni includono opzioni per l'acquisto di 264.000 azioni ordinarie nell'ambito del Piano di Incentivazione 2023 dell'azienda.

Le opzioni azionarie sono state concesse il 28 febbraio 2025, con un prezzo di esercizio di $14,17 per azione, corrispondente al prezzo di chiusura delle azioni ordinarie di Delcath in quella data. Il programma di vesting prevede che un terzo delle opzioni maturi dopo il primo anno, con i restanti due terzi che maturano in rate mensili uguali per 24 mesi. Le opzioni hanno un termine di dieci anni e richiedono un impiego continuativo per la maturazione.

Delcath Systems (Nasdaq: DCTH), una empresa de oncología intervencionista especializada en tratamientos para el cáncer de hígado, ha anunciado concesiones de incentivos de capital a seis nuevos empleados que se unieron en enero y febrero de 2025. Las concesiones incluyen opciones para comprar 264,000 acciones ordinarias bajo el Plan de Incentivos 2023 de la empresa.

Las opciones sobre acciones se otorgaron el 28 de febrero de 2025, con un precio de ejercicio de $14.17 por acción, igualando el precio de cierre de las acciones ordinarias de Delcath en esa fecha. El calendario de adquisición incluye un tercio de las opciones que se adquieren después del primer año, con los dos tercios restantes que se adquieren en cuotas mensuales iguales durante 24 meses. Las opciones tienen un plazo de diez años y requieren empleo continuo para la adquisición.

델카스 시스템즈 (Nasdaq: DCTH), 간암 치료를 전문으로 하는 중재적 종양학 회사가 2025년 1월과 2월에 합류한 6명의 신입 직원에게 주식 유인 보상을 발표했습니다. 이 보상에는 회사의 2023 유인 계획에 따라 264,000주의 보통주를 구매할 수 있는 옵션이 포함됩니다.

주식 옵션은 2025년 2월 28일에 부여되었으며, 주당 행사 가격은 $14.17로, 해당 날짜의 델카스 보통주의 종가와 일치합니다. 베스팅 일정은 첫 해가 지난 후 1/3의 옵션이 베스팅되며, 나머지 2/3는 24개월 동안 매월 동일한 금액으로 베스팅됩니다. 옵션은 10년의 기간을 가지며, 베스팅을 위해서는 지속적인 고용이 필요합니다.

Delcath Systems (Nasdaq: DCTH), une entreprise d'oncologie interventionnelle spécialisée dans les traitements du cancer du foie, a annoncé des attributions d'incitation en actions à six nouveaux employés qui ont rejoint en janvier et février 2025. Les attributions comprennent des options pour acheter 264 000 actions ordinaires dans le cadre du Plan d'Incitation 2023 de l'entreprise.

Les options d'achat d'actions ont été accordées le 28 février 2025, avec un prix d'exercice de 14,17 $ par action, correspondant au prix de clôture des actions ordinaires de Delcath à cette date. Le calendrier d'acquisition prévoit qu'un tiers des options acquiert des droits après la première année, les deux tiers restants acquérant des droits par versements mensuels égaux sur 24 mois. Les options ont une durée de dix ans et nécessitent un emploi continu pour l'acquisition des droits.

Delcath Systems (Nasdaq: DCTH), ein Unternehmen für interventionelle Onkologie, das sich auf die Behandlung von Leberkrebs spezialisiert hat, hat Aktienanreizvergaben an sechs neue Mitarbeiter angekündigt, die im Januar und Februar 2025 begonnen haben. Die Vergaben umfassen Optionen zum Kauf von 264.000 Aktien des Stammkapitals im Rahmen des Unternehmensplans von 2023.

Die Aktienoptionen wurden am 28. Februar 2025 gewährt, mit einem Ausübungspreis von 14,17 $ pro Aktie, was dem Schlusskurs der Delcath-Stammaktien an diesem Tag entspricht. Der Vesting-Zeitplan sieht vor, dass ein Drittel der Optionen nach dem ersten Jahr vestet, während die verbleibenden zwei Drittel in gleichen monatlichen Raten über 24 Monate vesten. Die Optionen haben eine Zehnjahreslaufzeit und erfordern eine fortgesetzte Beschäftigung für das Vesting.

Positive
  • Successful recruitment of six new employees indicating company growth
  • Implementation of equity-based compensation to align employee interests with shareholders
Negative
  • Potential dilution of existing shareholders from 264,000 new stock options

QUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to six individuals whose employment commenced in January and February of 2025.

The grants resulted in the right to purchase 264,000 shares of the Company’s common stock and are subject to the terms and conditions of the Company’s 2023 Inducement Plan (“Plan”). The options were granted on February 28, 2025, the date the Compensation Committee approved the stock option included within the equity inducements and are subject to an exercise price equal to $14.17, the closing price of Delcath’s common stock on February 28, 2025. One-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting in equal monthly installments over the following twenty-four months. The options have a ten-year term and the vesting of the options are subject to the employee’s continued employment with Delcath on each vesting date.

The above-described awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the terms of the Plan.

About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

Investor Relations:

ICR Westwicke

investorrelations@delcath.com

Source: Delcath Systems, Inc.

FAQ

What is the exercise price for Delcath's (DCTH) February 2025 inducement stock options?

The exercise price is $14.17, equal to Delcath's closing stock price on February 28, 2025.

How many shares are included in Delcath's (DCTH) February 2025 inducement grants?

The inducement grants include options to purchase 264,000 shares of common stock.

What is the vesting schedule for Delcath's (DCTH) February 2025 inducement options?

One-third vests after one year, with remaining two-thirds vesting monthly over 24 months, subject to continued employment.

How long is the term for Delcath's (DCTH) February 2025 inducement stock options?

The stock options have a ten-year term.
Delcath Sys

NASDAQ:DCTH

DCTH Rankings

DCTH Latest News

DCTH Stock Data

377.29M
31.46M
2.7%
41.33%
2.1%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
QUEENSBURY